S. Wallace

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

J. Bauman, Dennie V. Jones, K. Eaton, 2012, BMC Cancer.

A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.

C. Baik, K. Eaton, Rebecca L. Wood, 2021, Cancer treatment and research communications.

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

D. Wood, H. Vesselle, J. Bauman, 2019, BMC Cancer.

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

D. Hayes, N. Futran, E. Mendez, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results.

D. Hayes, N. Futran, U. Parvathaneni, 2010 .

Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC).

D. Mankoff, R. Martins, L. Carr, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC)

D. Mankoff, K. Eaton, R. Martins, 2008 .